Study #2024-0125
Phase I multicenter, open-label, first-in-human study of BMS-986497 (ORM-6151) in subjects with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
MD Anderson Study Status
Enrolling
Treatment Agent
BMS-986497
Description
The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study phase:
Phase I
Physician name:
Abhishek Maiti
Department:
Leukemia
For general questions about clinical trials:
1-855-319-9556
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.